AngioDynamics ANGO
$11.73 −$0.08 (-0.68%)
Market closed · Nov 6, 8:10 pm ET · Last extended-hours $11.73 0.00%
Open$11.62
Prev close$11.81
Day range$11.52 – $11.81
Volume363.7K
Market cap$493.30M
P/E (TTM)–
Dividend yield–
Fundamentals
Latest reported quarter: Q1, ended Aug 2026
Revenue$80.92M+6.9% YoY
Operating profit-$5.12M+35.2% YoY
Net profit-$7.10M+34.9% YoY
Diluted EPS-$0.17+34.6% YoY
Free cash flow-$15.71M+5.6% YoY
Operating cash flow-$15.33M
Revenue, last 8 quarters
Net profit, last 8 quarters
Diluted EPS by quarter
Free cash flow by quarter
Annual revenue
Profitability & balance sheet
Gross margin55.7%
Operating margin-6.0%
Net margin-10.1%
Return on equity-19.2%
Return on assets-13.0%
Return on invested capital-19.2%
Current ratio2.40
Liabilities / assets32.2%
Cash & investments$33.97M
Net cash (debt)$33.97M
Free cash flow / sales0.4%
Where the revenue comes from
Quarter 2026/FY
By business line
By region
Income statement
| Line item | 2027 Q1 | 2026 ANNUAL | 2026 Q4 | 2026 Q3 | 2026 Q2 |
|---|---|---|---|---|---|
| Total Revenue as Reported | $80.92M | $320.17M | $86.61M | $78.42M | $79.43M |
| Total Operating Revenue | $80.92M | $320.17M | $86.61M | $78.42M | $79.43M |
| Cost of Revenue | $32.88M | $145.28M | $39.83M | $36.94M | $34.65M |
| Gross Profit | $48.04M | $174.89M | $46.77M | $41.48M | $44.78M |
| Operating Expense | $53.16M | $197.22M | $52.29M | $47.91M | $47.27M |
| Selling and Admin Expenses | $42.45M | $157.09M | $41.39M | $38.16M | $36.86M |
| -Selling & Marketing Expense | $29.99M | $113.40M | $31.12M | $27.44M | $26.71M |
| -General & Admin Expense | $12.47M | $43.69M | $10.27M | $10.72M | $10.15M |
| Research & Development | $7.98M | $29.45M | $8.18M | $7.08M | $7.77M |
| Depreciation & Amortization & Depletion | $2.73M | $10.68M | $2.72M | $2.67M | $2.64M |
| -Depreciation & Amortization | $2.73M | $10.68M | $2.72M | $2.67M | $2.64M |
| Operating Profit | -$5.12M | -$22.33M | -$5.51M | -$6.43M | -$2.49M |
| Net Non-Operating Interest Income (Expense) | -$88,000.00 | -$299,000.00 | -$105,000.00 | -$88,000.00 | -$102,000.00 |
| Non-Operating Interest Expense | $88,000.00 | – | – | – | – |
| Other Income (Expense) | -$2.09M | -$13.67M | -$5.42M | -$1.56M | -$3.76M |
| Special Income (Charges) | -$2.18M | -$17.60M | -$4.68M | -$6.52M | -$3.64M |
| -Less:Restructuring and Mergern & Acquisition | $1.78M | $15.59M | $4.50M | $6.38M | $2.16M |
| -Less:Other Special Charges | $406,000.00 | $2.01M | $181,000.00 | $146,000.00 | $1.47M |
| Other Non-Operating Income (Expenses) | $94,000.00 | $3.93M | -$735,000.00 | $4.97M | -$128,000.00 |
| Pretax Profit | -$7.30M | -$36.30M | -$11.04M | -$8.07M | -$6.36M |
| Tax | -$199,000.00 | $442,000.00 | $370,000.00 | $12,000.00 | -$5,000.00 |
| Net Profit | -$7.10M | -$36.74M | -$11.41M | -$8.08M | -$6.35M |
| Profit from Continuing Operations | -$7.10M | -$36.74M | -$11.41M | -$8.08M | -$6.35M |
| Net Income to Parent Company | -$7.10M | -$36.74M | -$11.41M | -$8.08M | -$6.35M |
| Net Income to Common Stockholders | -$7.10M | -$36.74M | -$11.41M | -$8.08M | -$6.35M |
| Basic EPS | -$0.17 | -$0.88 | -$0.27 | -$0.19 | -$0.15 |
| Diluted EPS | -$0.17 | -$0.88 | -$0.27 | -$0.19 | -$0.15 |
| Total Other Finance Costs | – | $299,000.00 | $105,000.00 | $88,000.00 | $102,000.00 |
| -Less:Impairment of Capital Assets | – | $0.00 | – | – | – |
| -Gain on Sale of Property/Plant/Equipment | – | $0.00 | – | – | – |
Balance sheet
| Line item | 2027 Q1 | 2026 ANNUAL | 2026 Q4 | 2026 Q3 | 2026 Q2 |
|---|---|---|---|---|---|
| Total Assets | $241.93M | $267.16M | $267.16M | $260.68M | $269.68M |
| Total Current Assets | $143.00M | $163.39M | $163.39M | $155.55M | $161.35M |
| Cash and Cash Equivalents & Short-Term Investments | $33.97M | $53.86M | $53.86M | $37.81M | $41.64M |
| -Cash and Cash Equivalents | $33.97M | $53.86M | $53.86M | $37.81M | $41.64M |
| Receivables | $44.91M | $48.51M | $48.51M | $45.55M | $44.43M |
| -Accounts Receivable | $44.91M | $48.33M | $48.33M | $45.55M | $44.43M |
| Inventory | $54.95M | $52.44M | $52.44M | $58.58M | $65.57M |
| Other Current Assets | $9.17M | $3.59M | $3.59M | $13.61M | $9.71M |
| Total Non-Current Assets | $98.93M | $103.77M | $103.77M | $105.13M | $108.33M |
| Net PPE | $27.73M | $27.10M | $27.10M | $29.14M | $30.53M |
| Goodwill and Other Intangible Assets | $61.89M | $67.21M | $67.21M | $65.49M | $66.73M |
| -Other Intangible Assets | $61.89M | $67.21M | $67.21M | $65.49M | $66.73M |
| Other Non-Current Assets | $9.31M | $9.46M | $9.46M | $10.50M | $11.07M |
| Total Liabilities | $77.97M | $96.34M | $96.34M | $87.32M | $93.35M |
| Total Current Liabilities | $59.69M | $74.72M | $74.72M | $66.07M | $71.96M |
| Payables | $26.97M | $31.99M | $31.99M | $29.63M | $35.89M |
| -Accounts Payable | $26.58M | $31.51M | $31.51M | $29.11M | $35.39M |
| -Total Tax Payable | $393,000.00 | $476,000.00 | $476,000.00 | $524,000.00 | $417,000.00 |
| Current Accrued Expenses | $26.29M | $36.30M | $36.30M | $29.97M | $27.76M |
| Current Deferred Liabilities | $236,000.00 | $288,000.00 | $288,000.00 | $282,000.00 | $277,000.00 |
| Other Current Liabilities | $4.30M | $4.30M | $4.30M | $4.66M | $6.72M |
| Total Non-Current Liabilities | $18.28M | $21.62M | $21.62M | $21.26M | $21.39M |
| Non-Current Deferred Liabilities | $4.68M | $5.32M | $5.32M | $4.55M | $4.33M |
| Other Non-Current Liabilities | $13.60M | $16.31M | $16.31M | $16.70M | $17.05M |
| Total Equity | $163.96M | $170.83M | $170.83M | $173.36M | $176.33M |
| Stockholders' Equity | $163.96M | $170.83M | $170.83M | $173.36M | $176.33M |
| Capital Stock | $388,000.00 | $387,000.00 | $387,000.00 | $387,000.00 | $386,000.00 |
| -Common Stock | $388,000.00 | $387,000.00 | $387,000.00 | $387,000.00 | $386,000.00 |
| -Preferred Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Additional Paid-In Capital | $639.31M | $636.08M | $636.08M | $632.18M | $628.78M |
| Retained Earnings | -$473.04M | -$465.94M | -$465.94M | -$454.53M | -$446.45M |
| Less: Treasury Stock | $7.38M | $7.38M | $7.38M | $7.38M | $7.38M |
| Gains/Losses Not Affecting Retained Earnings | $4.68M | $7.68M | $7.68M | $2.71M | $998,000.00 |
| -Other Receivables | – | $189,000.00 | $189,000.00 | – | – |
| Prepaid Assets | – | $4.71M | $4.71M | – | – |
| Current Deferred Assets | – | $290,000.00 | $290,000.00 | – | – |
| -Gross PPE | – | $107.81M | $107.81M | – | – |
| -Accumulated Depreciation | – | -$80.71M | -$80.71M | – | – |
| -Other Payable | – | – | – | – | $86,000.00 |
Cash flow
| Line item | 2027 Q1 | 2026 ANNUAL | 2026 Q4 | 2026 Q3 | 2026 Q2 |
|---|---|---|---|---|---|
| Operating Cash Flow | -$15.33M | $3.09M | $17.45M | -$3.11M | $4.66M |
| Net cash flow from continuing operations | -$15.33M | $3.09M | $17.45M | -$3.11M | $4.66M |
| Net Income from Continuing Operations | -$7.10M | -$36.74M | -$11.41M | -$8.08M | -$6.35M |
| Gain/Loss from Continuing Operations | $81,000.00 | – | – | – | $307,000.00 |
| Depreciation & Depletion & Amortization | $5.50M | $22.96M | $5.60M | $5.59M | $5.82M |
| Deferred Tax | -$306,000.00 | $143,000.00 | $150,000.00 | $57,000.00 | -$48,000.00 |
| Other Non-Cash Items | -$269,000.00 | $3.81M | $1.58M | $737,000.00 | $718,000.00 |
| Change in Working Capital | -$17.68M | -$2.66M | $16.51M | -$4.45M | $1.56M |
| -Change in Receivables | $3.47M | -$5.75M | -$2.90M | -$1.42M | -$1.57M |
| -Change in Inventory | -$2.72M | $10.05M | $6.46M | $7.06M | -$3.28M |
| -Change in Prepaid Assets | -$1.02M | -$1.12M | $5.25M | -$4.08M | $3.23M |
| -Change in Payables and Accrued Expense | -$17.42M | -$5.83M | $7.70M | -$6.01M | $3.18M |
| Net cash flow from investing | -$3.15M | -$5.95M | -$1.27M | -$1.51M | -$1.62M |
| Net Cash Flow from Continuing Investing Activities | -$3.15M | -$5.95M | -$1.27M | -$1.51M | -$1.62M |
| Net PPE Purchase and Sale | -$379,000.00 | -$2.58M | -$413,000.00 | -$1.02M | -$422,000.00 |
| Net Other Investing Changes | -$2.77M | -$3.37M | -$857,000.00 | -$492,000.00 | -$1.20M |
| Financing Cash Flow | -$1.38M | $564,000.00 | -$108,000.00 | $621,000.00 | -$92,000.00 |
| Net Cash Flow from Continuing Financing Activities | -$1.38M | $564,000.00 | -$108,000.00 | $621,000.00 | -$92,000.00 |
| Proceeds from Stock Option Exercised | -$1.28M | $939,000.00 | -$11,000.00 | $716,000.00 | $0.00 |
| Net Other Financing Charges | -$99,000.00 | -$375,000.00 | -$97,000.00 | -$95,000.00 | -$92,000.00 |
| Ending Cash Balance | $33.97M | $53.86M | $53.86M | $37.81M | $41.64M |
| Net Change in Cash | -$19.85M | -$2.30M | $16.07M | -$4.00M | $2.95M |
| Beginning Cash Balance | $53.86M | $55.89M | $37.81M | $41.64M | $38.76M |
| Effect of Exchange Rate Changes | -$38,000.00 | $267,000.00 | -$20,000.00 | $168,000.00 | -$72,000.00 |
| Free Cash Flow | -$15.71M | $508,000.00 | $17.04M | -$4.13M | $4.24M |
| Net Intangibles Purchase and Sale | – | $0.00 | – | – | – |
| Net Issuance Payments Of Debt | – | $0.00 | – | – | – |
| Net Common Stock Issuance | – | $0.00 | $0.00 | $0.00 | $0.00 |
No comments yet — be the first to weigh in on ANGO.
Sign in to join the discussion.